20/20 Biolabs OKs 500M-share authorization
Stockholders of 20/20 Biolabs approved a charter amendment increasing authorized common shares from 50 million to 500 million.
Rhea-AI Filing Summary
20/20 Biolabs, Inc. (AIDX) reports that stockholders approved a charter amendment at the adjourned annual meeting held on September 16, 2026. The amendment increases the number of shares of common stock the company is authorized to issue from 50 million to 500 million.
As of the June 22, 2026 record date, 12,251,198 shares of common stock were outstanding and entitled to vote, and 4,256,837 shares were represented in person or by proxy, constituting a quorum. Proposal 3 passed with 3,028,609 votes for, 1,155,607 against, and 72,621 abstentions.
Positive
- None.
Negative
- None.
Filing Explained
The approved amendment raises 20/20 Biolabs’ authorized common-share ceiling from
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Authorized common stock before amendment: 50,000,000 shares
Authorized common stock after amendment: 500,000,000 shares
Shares outstanding at record date: 12,251,198 shares
+4 more
7 metrics
Authorized common stock before amendment
50,000,000 shares
Number of common shares the company was authorized to issue before the charter amendment
Authorized common stock after amendment
500,000,000 shares
Number of common shares the company is authorized to issue after stockholder approval of Proposal 3
Shares outstanding at record date
12,251,198 shares
Common stock outstanding and entitled to vote as of June 22, 2026
Shares represented at adjourned meeting
4,256,837 shares
Common shares represented in person or by valid proxies at the September 16, 2026 adjourned meeting
Votes for Proposal 3
3,028,609 votes
Votes cast in favor of the charter amendment to increase authorized common stock
Votes against Proposal 3
1,155,607 votes
Votes cast against the charter amendment to increase authorized common stock
Abstentions on Proposal 3
72,621 votes
Abstentions on the charter amendment proposal
Key Terms
authorized to issue, Second Amended and Restated Certificate of Incorporation, definitive proxy statement, quorum, +1 more
5 terms
authorized to issue regulatory
"increase the number of shares of common stock that the Company is authorized to issue"
Second Amended and Restated Certificate of Incorporation regulatory
"approved an amendment and restatement of the Company’s Second Amended and Restated Certificate"
definitive proxy statement regulatory
"described in detail in the Company’s definitive proxy statement, dated June 23, 2026"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
quorum regulatory
"4,256,837 shares of common stock were represented in person or by valid proxies ... constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
Emerging Growth Company regulatory
"Emerging Growth Company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What charter change did 20/20 Biolabs (AIDX) stockholders approve?
Stockholders approved an amendment and restatement of the certificate of incorporation to increase authorized common stock from 50 million shares to 500 million shares, as described in the company’s definitive proxy statement dated June 23, 2026.
What was the quorum at the 20/20 Biolabs adjourned meeting on September 16, 2026?
A total of 4,256,837 shares of common stock were represented in person or by valid proxies at the adjourned meeting, which the company states constituted a quorum for Proposal 3.
What were the vote results for Proposal 3 at 20/20 Biolabs (AIDX)?
Proposal 3 received 3,028,609 votes for, 1,155,607 votes against, and 72,621 abstentions, resulting in stockholder approval of the charter amendment increasing authorized common stock.
When was the adjourned 20/20 Biolabs annual meeting held for Proposal 3?
The adjourned portion of the annual meeting to consider Proposal 3 was held on September 16, 2026 at 10:00 a.m. Eastern Time.
Who signed the 20/20 Biolabs (AIDX) report about the charter amendment?
The report was signed on behalf of 20/20 Biolabs, Inc. by Jonathan Cohen, the company’s Chief Executive Officer, dated September 18, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
